H.C. Wainwright Reiterates Buy Rating on Palvella Therapeutics (PVLA)

July 22, 2026 6:52 AM

H.C. Wainwright analyst Andrew Fein reiterated a Buy rating and $270.00 price target on Palvella Therapeutics (NASDAQ: PVLA).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found